The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective

Eden David, Benjamin Ungar, Yael Renert-Yuval, Paola Facheris, Ester del Duca, Emma Guttman-Yassky

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Atopic dermatitis (AD) is one of the most common, chronic inflammatory skin diseases with a significant physical, emotional and socioeconomic burden. In recent years the understanding of AD pathogenesis has expanded from the Th2-centred perspective, with the recognition of the involvement of other immune axes. In different AD endotypes, influenced by environment, genetics and race, transcriptomic profiles have identified differing contributions of multiple immune axes such as, Th17, Th22 and Th1. The enriched pathogenic model of AD has catalysed the development of numerous biologic therapies targeting a range of key molecules implicated in disease progression. Currently, dupilumab and tralokinumab, which both target the Th2 pathway, are the only approved biologic therapies for AD in the United States and Europe. New biologic therapies in development, however, target different Th2-pathway molecules along with cytokines in other immune axes, including Th17 and Th22, offering promise for varied treatments for this heterogeneous disease. As the biologic pipeline advances, the integration into clinical practice and approval of these experimental biologics may provide more effective, tailored therapeutic solutions and illuminate on the pathologic processes of AD across a broader, more diverse patient population.

Original languageEnglish
Pages (from-to)156-172
Number of pages17
JournalClinical and Experimental Allergy
Issue number2
StatePublished - Feb 2023


  • Th2 pathway
  • atopic dermatitis
  • biologics


Dive into the research topics of 'The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective'. Together they form a unique fingerprint.

Cite this